Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) is a clinical-stage biotechnology company applying its proprietary Anticalin technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Anticalins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Pieris’ libraries of more than 100 billion different Anticalins can virtually bind to any target of interest. For more information, visit the company’s website at www.pieris.com.